Whalesbook
📉 The Financial Deep Dive
Nevelix Pharmaceuticals Limited, formerly Trimurti Limited, has delivered a stellar performance for the quarter ended December 31, 2025 (Q3 FY26), showcasing explosive growth driven by its strategic pivot to the pharmaceutical sector.
The Numbers:
Income from Operations for Q3 FY26 leaped by an astonishing 811.47% year-on-year, reaching ₹4,840.25 Cr compared to ₹529.98 Cr in Q3 FY25. Sequentially, revenue grew by a robust 33.11% from ₹3,635.89 Cr in Q2 FY26.
Net Profit mirrored this dramatic ascent, soaring 579.72% YoY to ₹100.44 Cr from ₹14.79 Cr in Q3 FY25. Quarter-on-quarter, Net Profit surged by 88.44% to ₹100.44 Cr from ₹53.31 Cr in Q2 FY26. Earnings Per Share (EPS) basic for continuing operations climbed 286.67% YoY to ₹0.58, up from ₹0.15 in the prior year, and increased 56.76% QoQ from ₹0.37.
The Quality & Context:
While profitability metrics like EBITDA and margins were not detailed in the filing excerpt, the significant jump in Net Profit relative to revenue growth suggests potential margin expansion. However, a critical observation is the 72.99% YoY increase in Paid-up Equity Capital, from ₹995.00 Cr to ₹1721.50 Cr. This substantial equity dilution requires further investigation to understand its impact on shareholder value and whether it was matched by proportionate asset growth or funding for new ventures.
The Grill:
No information regarding management guidance, concall highlights, or analyst expectations was available in the provided text. This leaves investors without direct forward-looking commentary or consensus views.
🚩 Risks & Outlook:
The primary risk for investors lies in understanding the sustainability of this hyper-growth and the implications of the significant equity increase. The company's focus has evidently shifted to 'Pharmaceutical Research & Analysis and Manufacturing & Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'. Future performance will hinge on execution within this new business domain and efficient capital deployment. Investors should closely monitor subsequent quarterly results and any disclosures related to the use of the increased equity capital.